HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Free via Open Access: OA OA Full Text Free Full Text (PDF) Free OA All Versions of this Article: fj.09-134643v1 23/11/3906    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Boyle, G. Articles by Ali, S. Search for Related Content PubMed PubMed Citation Articles by O'Boyle, G. Articles by Ali, S.

Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12

Applied Immunobiology and Transplantation Research Group, Institute of Cellular Medicine, Medical School, University of Newcastle, Newcastle upon Tyne, UK

² Correspondence: Applied Immunobiology and Transplantation Research Group, Institute of Cellular Medicine, Medical School, University of Newcastle, Newcastle upon Tyne, NE2 4HH UK. E-mail: j.a.kirby{at}ncl.ac.uk

Interaction between chemokines and heparan sulfate (HS) is essential for leukocyte recruitment during inflammation. Previous studies have shown that a non-HS-binding mutant form of the inflammatory chemokine CCL7 can block inflammation produced by wild-type chemokines. This study examined the anti-inflammatory mechanism of a non-HS-binding mutant of the homeostatic chemokine CXCL12. Initial experiments demonstrated that mutant CXCL12 was an effective CXCR4 agonist. However, this mutant chemokine failed to promote transendothelial migration in vitro and inhibited the haptotactic response to wild-type CCL7, CXCL12, and CXCL8, and naturally occurring chemoattractants in synovial fluid from the rheumatoid synovium, including CCL2, CCL7, and CXCL8. Notably, intravenous administration of mutant CXCL12 also inhibited the recruitment of leukocytes to murine air pouches filled with wild-type CXCL12. Following intravenous administration, wild-type CXCL12 was cleared from the circulation rapidly, while the mutant chemokine persisted for >24 h. Chronic exposure to mutant CXCL12 in the circulation reduced leukocyte-surface expression of CXCR4, reduced the chemotactic response of these cells to CXCL12, and inhibited normal chemokine-mediated induction of adhesion between the 4β1 integrin, VLA-4, and VCAM-1. These data demonstrate that systemic administration of non-HS-binding variants of CXCL12 can mediate a powerful anti-inflammatory effect through chemokine receptor desensitization.—O’Boyle, G., Mellor, P., Kirby, J. A., Ali, S. Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12.

Key Words: chemokine • glycosaminoglycan • G-protein-coupled receptors • integrin adhesion • receptor desensitization

This article has been cited by other articles:

				I. C. Severin, J. P. Gaudry, Z. Johnson, A. Kungl, A. Jansma, B. Gesslbauer, B. Mulloy, C. Power, A. E. I. Proudfoot, and T. Handel Characterization of the Chemokine CXCL11-Heparin Interaction Suggests Two Different Affinities for Glycosaminoglycans J. Biol. Chem., June 4, 2010; 285(23): 17713 - 17724. [Abstract] [Full Text] [PDF]